Asthma warning: Adults with asthma who take drugs such as salmeterol alone have an increased risk of death from asthma problems. Also, children and adolescents with asthma who take salmeterol alone ...

The safe and appropriate use of long-acting beta-agonists (LABAs) for the treatment of asthma has been widely debated. In two large clinical trials, investigators found a potential risk of serious ...

Long-acting beta-agonists (LABAs) have been shown to increase the risk of asthma-related death among adults and the risk of asthma-related hospitalization among children. It is unknown whether the ...

I have a few questions about fluticasone-salmeterol. Is it true that the current guidelines call for dual therapy as opposed to monotherapy, ie, inhaled steroids? Also, if a child has recurrent use of ...

Objective: To compare the efficacy and tolerability of a salmeterol/fluticasone propionate (FP) combination product (50/100µg twice daily) with budesonide (BUD) at a four-fold higher microgram dose ...

Fluticasone-salmeterol combination does not cause more serious asthma-related events than fluticasone in moderate-to-severe asthma, indicated a study. Routine use of short-acting beta blockers like ...

asthma The risk of serious asthma-related events was no greater with the combination of long-acting beta-agonist (LABA) salmeterol + the inhaled glucocorticoid, fluticasone propionate, versus ...

Discover comprehensive details about Salmeterol and Fluticasone, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated ...

Initiation of fluticasone propionate–salmeterol after a COPD-related hospitalization or ED visit decreased the risk of a recurrent event and reduced COPD-related medical costs. Objectives: To quantify ...

Efficacy trials suggest that extra-fine particle beclometasone dipropionate-formoterol (efBDP-FOR) is comparable to fluticasone propionate-salmeterol (FP-SAL) in preventing asthma exacerbations at a ...

This cost-utility analysis compares the cost-effectiveness of salmeterol, fluticasone propionate, combination salmeterolfluticasone, and no maintenance therapy in chronic obstructive pulmonary disease ...